We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nevada’s action marks a growing trend among states to try to rein in the rising costs of prescription drugs — especially as the latest federal attempt at allowing Medicare to negotiate the price of some medications is stalled in the Senate. Read More
AstraZeneca’s and Sanofi’s investigational long-acting antibody aimed at infants with respiratory syncytial virus (RSV) had positive results in its phase 3 trial, making it the first potential immunization to show protection against RSV in the general infant population in a phase 3 trial, the companies said. Read More
Gantenerumab, another anti-amyloid antibody, is entering the race to find an effective therapy for Alzheimer’s disease (AD), with an ambitious four-year study in presymptomatic, amyloid-positive subjects. Read More
To clarify the FDA’s recommendations on quickly and effectively removing potentially harmful drugs and devices from the market, the agency has published a final guidance focused on recall readiness. Read More
The FDA has begun releasing a court-mandated trove of documents pertaining to the agency’s review of Pfizer/BioNTech’s COVID-19 vaccine — which the agency authorized for emergency use in December 2020 before granting full approval in August 2021. Read More
The Sackler family and OxyContin maker Purdue Pharma have agreed to pay $6 billion in a revised bankruptcy settlement proposal with a group of holdout states who appealed a previously approved settlement plan. Read More
In his State of the Union address on Tuesday, President Joe Biden reiterated his desire to drive down the price of pharmaceuticals in the U.S., a move that was thwarted in January after his massive spending package Build Back Better plan didn’t make it through the Senate. Read More
Sanofi reported that the average net price in its U.S. drugs after rebates and discounts decreased by 1.3 percent in 2021, continuing a six-year downward trend. Read More